Results 221 to 230 of about 54,679 (264)

Ipilimumab

Drugs, 2012
exaly   +5 more sources

Ipilimumab

Reactions Weekly, 2017
  +12 more sources

Ipilimumab

Reactions Weekly, 2018
  +10 more sources

First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial.

The Lancet Oncology, 2021
BACKGROUND First-line nivolumab plus ipilimumab has shown improved overall survival in patients with advanced non-small-cell lung cancer (NSCLC). We aimed to investigate whether the addition of a limited course (two cycles) of chemotherapy to this ...
L. Paz-Ares, T. Ciuleanu, M. Cobo, M. Schenker, B. Żurawski, J. Menezes, E. Richardet, J. Bennouna, E. Felip, Ó. Juan-Vidal, A. Alexandru, H. Sakai, A. Lingua, P. Salman, P. Souquet, P. de Marchi, C. Martin, M. Pérol, A. Scherpereel, Shun Lu, T. John, D. Carbone, S. Meadows-Shropshire, S. Agrawal, A. Oukessou, Jinchun Yan, M. Reck   +26 more
semanticscholar   +1 more source

First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study

Journal of Clinical Oncology, 2021
PURPOSE Nivolumab received US Food and Drug Administration approval as a single agent or in combination with ipilimumab in patients with microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC) that ...
H. Lenz, E. Van Cutsem, Maria Luisa Limon, K. Wong, A. Hendlisz, M. Aglietta, P. García-Alfonso, B. Neyns, G. Luppi, D. Cardin, T. Dragovich, U. Shah, S. Abdullaev, J. Gricar, J. Ledeine, M. Overman, S. Lonardi   +16 more
semanticscholar   +1 more source

Ipilimumab in melanoma

Expert Review of Anticancer Therapy, 2012
Ipilimumab is a fully human monoclonal antibody directed against the cytotoxic T-lymphocyte antigen-4 receptor. Blocking cytotoxic T-lymphocyte antigen-4 signaling has been shown to enhance T-cell activation and to amplify T-cell-mediated immunity. Ipilimumab, either as a single agent or in combination with gp100 vaccination, significantly prolonged ...
openaire   +5 more sources

Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): a randomised, open-label, phase 3 trial.

The Lancet
BACKGROUND CheckMate 8HW prespecified dual primary endpoints, assessed in patients with centrally confirmed microsatellite instability-high or mismatch repair-deficient status: progression-free survival with nivolumab plus ipilimumab compared with ...
Thierry Andre, E. Élez, H. Lenz, Lars Henrik Jensen, Y. Touchefeu, Eric Van Cutsem, R. Garcia-Carbonero, D. Tougeron, Guillermo Mendez, M. Schenker, C. de la Fouchardière, M. L. Limon, T. Yoshino, Jin Li, J. L. Manzano Mozo, Laetitia Dahan, G. Tortora, Myriam Chalabi, E. Goekkurt, M. Braghiroli, Rohit Joshi, T. Çil, Francine Aubin, E. Cela, Tian Chen, Ming Lei, Lixian Jin, S. Blum, S. Lonardi   +28 more
semanticscholar   +1 more source

Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma

New England Journal of Medicine
Background The phase 3 CheckMate 067 trial has demonstrated improved survival with nivolumab-plus-ipilimumab or nivolumab monotherapy compared with ipilimumab monotherapy in patients with advanced melanoma. Here, we report the final, 10-year results from
J. Wolchok, V. Chiarion-Sileni, Piotr Rutkowski, C. Cowey, D. Schadendorf, John Wagstaff, P. Queirolo, R. Dummer, Marcus O. Butler, A. Hill, M. Postow, C. Gaudy-Marqueste, Theresa Medina, Christopher D. Lao, J. Walker, I. Márquez-Rodas, John B. A G. Haanen, M. Guidoboni, Michele Maio, P. Schöffski, M. Carlino, S. Sandhu, Céleste Lebbé, P. Ascierto, Georgina V. Long, C. Ritchings, A. Nassar, M. Askelson, M. Benito, Wenjia Wang, F. Hodi, J. Larkin   +31 more
semanticscholar   +1 more source

Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma.

New England Journal of Medicine
BACKGROUND Phase 1-2 trials involving patients with resectable, macroscopic stage III melanoma have shown that neoadjuvant immunotherapy is more efficacious than adjuvant immunotherapy.
C. Blank, M. Lucas, R. Scolyer, B. A. Van de Wiel, A. Menzies, M. Lopez-Yurda, L. Hoeijmakers, R. Saw, J. Lijnsvelt, Nigel G. Maher, Saskia M. Pulleman, Maria Gonzalez, A. Torres Acosta, W. V. van Houdt, Serigne N. Lo, Anke M. J. Kuijpers, A. Spillane, W. Klop, T. Pennington, C. Zuur, K. Shannon, Beatrijs A. Seinstra, R. Rawson, J. Haanen, S. Ch’ng, K. Naipal, Jonathan Stretch, J. V. van Thienen, M. Rtshiladze, S. Wilgenhof, R. Kapoor, Aafke Meerveld-Eggink, L. Grijpink-Ongering, A. V. Van Akkooi, I. Reijers, D. Gyorki, D. Grünhagen, F. Speetjens, Sonja B. Vliek, J. Placzke, L. Spain, R. C. Stassen, M. Amini-Adle, C. Lebbé, M. Faries, Caroline Robert, P. Ascierto, R. V. van Rijn, F. van den Berkmortel, D. Piersma, A. Van der Westhuizen, Gerard Vreugdenhil, M. J. Aarts, Marion A. Stevense-den Boer, V. Atkinson, M. Khattak, M. C. Andrews, A. van den Eertwegh, M. Boers-Sonderen, G. Hospers, M. Carlino, J. D. de Groot, E. Kapiteijn, K. Suijkerbuijk, Piotr Rutkowski, S. Sandhu, A. V. D. van der Veldt, Georgina V. Long   +67 more
semanticscholar   +1 more source

Nivolumab plus Ipilimumab in Microsatellite-Instability-High Metastatic Colorectal Cancer.

New England Journal of Medicine
BACKGROUND Patients with microsatellite-instability-high (MSI-H) or mismatch-repair-deficient (dMMR) metastatic colorectal cancer have poor outcomes with standard chemotherapy with or without targeted therapies.
Thierry Andre, E. Élez, Eric Van Cutsem, Lars Henrik Jensen, Jaafar Bennouna, Guillermo Mendez, M. Schenker, C. de la Fouchardière, M. L. Limon, T. Yoshino, Jin Li, H. Lenz, J. L. Manzano Mozo, G. Tortora, R. Garcia-Carbonero, Laetitia Dahan, M. Chalabi, Rohit Joshi, E. Goekkurt, M. Braghiroli, T. Çil, E. Cela, Tian Chen, Ming Lei, M. Dixon, S. Abdullaev, S. Lonardi   +26 more
semanticscholar   +1 more source